Drug Database
Back to search

Poland· PL-100536232

Adenosine Polpharma

A adenosine product containing adenosinum, registered in Poland by Zakłady Farmaceutyczne POLPHARMA S.A.. The same ATC class is registered in 16 of our 19 countries.

ATC C01EB10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAdenosine PolpharmaATCC01EB10REGISTER NO.PL-100536232PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about adenosinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Adenosine is registered in 16 of 19 countries.

Countries holding a registration under ATC C01EB10 (adenosine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search adenosine products by name

Adenosine · ATC C01EB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Adenosinum
Manufacturer
Zakłady Farmaceutyczne POLPHARMA S.A.
Country
Poland (PL)
ATC code
C01EB10
ATC class
Adenosine
Defined daily dose
15 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    5903060632660

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

181 interactions on record for adenosine.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check adenosine against other medicinesHow interaction checks work

Adenosine · interactions on record

181 records

  • 38 severe
  • 90 moderate
  • 1 minor
  • 52 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Adenosine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All adenosine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Adenosin Baxter, Adenosin Hikma
  • Belgium · Adenocor, Adenosine Fresenius Kabi
  • Cyprus · Caden
  • Czechia · Adenocor
  • Germany · Adenoscan, Adenosin Altamedics
  • Denmark · Adenocor, Adenosin Fresenius Kabi
  • Estonia · Adenosin Life Medical
  • Spain · Adenocor, Adenoscan
  • Finland · Adenosin Life Medical, Adenosin Macure
  • France · Adenoscan, Adenosine Hikma
  • United Kingdom (Northern Ireland) · Adenocor, Adenoscan
  • Greece · Adenorythm
  • Hungary · Adenocor
  • Ireland · Adenocor, Adenosine
  • Italy · Adenoscan, Adenosina Hikma
  • Lithuania · Adenosine Life Medical
  • Luxembourg · Adenocor
  • Netherlands · Adenocor, Adenosine Fresenius Kabi
  • Norway · Adenosin Life Medical, Adenosin Macure
  • Portugal · Adenoscan, Adenosina Baxter
  • Sweden · Adenosin Life Medical, Adenosin Macure
  • Slovakia · Adenocor

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bbbff40c-5016-4b55-bcb6-301fd24f8f95
GET /v1/drugs/bbbff40c-5016-4b55-bcb6-301fd24f8f95?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "3 mg/ml",
  "packaging": "5903060632660 ¦ Lz ¦ 166698\n6 fiol. 2 ml",
  "substance": "Adenosinum 3 mg/ml",
  "common_name": "Adenosinum",
  "pl_product_id": "100536232",
  "pozwolenie_nr": "153/26",
  "auth_procedure": "IR",
  "authorisation_validity": "2031-04-27"
}
API referenceMCP serverPlans

See everything about adenosine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console